MyChesCo on MSN10mon
Antennova Marks Milestone in Cancer Treatment with Promising Early Results from Anti-CD24 Antibody Trialan innovative anti-CD24 antibody. This trial, named the PERFORM trial, is focused on patients with advanced solid tumors or B ...
OncoImmune develops novel immune-modulators targeting innate checkpoint mechanisms involving CD24–Siglec10 signaling as well as potential best-in-class anti-CTLA-4 antibody therapy that can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback